• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用“正确轨道”模型管理胰腺癌患者。

Management of Patients With Pancreatic Cancer Using the "Right Track" Model.

机构信息

Scientific and Medical Affairs, Pancreatic Cancer Action Network, Los Angeles, CA, USA.

Department of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.

出版信息

Oncologist. 2023 Jul 5;28(7):584-595. doi: 10.1093/oncolo/oyad080.

DOI:10.1093/oncolo/oyad080
PMID:37043728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10322133/
Abstract

Pancreatic cancer is one of the few cancer types in the US with incidence and death rates continuing to rise. As the disease threatens to become the second leading cause of cancer-related deaths in the country, it is imperative to review the best practices currently available to extend and improve patient lives. To provide a roadmap for healthcare professionals detecting, diagnosing, and caring for patients with pancreatic cancer as a supplement to national guidelines focused on recommended treatment regimens, the Pancreatic Cancer Action Network (PanCAN)'s Scientific and Medical Affairs staff and expert Scientific and Medical Advisory Board have created a series of position statements. The statements are based upon scientific evidence and clinical observations published in the literature and research conducted through PanCAN's internal programs and initiatives. This review summarizes the rationale and sources for these position statements related to diagnosis, treatment, and care for pancreatic cancer and provides information about resources to make these recommendations accessible to patients and their medical teams. Pancreatic cancer is a complex and extremely challenging disease. Beyond treatment recommendations outlined in national guidelines, steps can be taken to help patients feel better and live longer. Under the framework of the "Right Track" model-right team, right tests, right treatments, data sharing-PanCAN's position statements can provide supplementary guidance to healthcare professionals for the short- and long-term management of patients with the disease.

摘要

胰腺癌是美国少数几种发病率和死亡率仍在持续上升的癌症类型之一。由于这种疾病有可能成为美国第二大致癌相关死亡原因,因此必须审查目前可延长和改善患者生命的最佳实践。为了为医疗保健专业人员提供检测、诊断和治疗胰腺癌患者的路线图,作为专注于推荐治疗方案的国家指南的补充,胰腺癌行动网络(PanCAN)的科学和医学事务人员以及专家科学和医学咨询委员会制定了一系列立场声明。这些声明基于在文献中发表的科学证据和临床观察,以及通过 PanCAN 的内部计划和倡议进行的研究。本综述总结了与胰腺癌诊断、治疗和护理相关的这些立场声明的基本原理和来源,并提供了有关资源的信息,以使这些建议能够为患者及其医疗团队所获得。胰腺癌是一种复杂且极具挑战性的疾病。除了国家指南中概述的治疗建议外,还可以采取措施帮助患者感觉更好并延长生存期。在“正确轨道”模型的框架下——正确的团队、正确的检测、正确的治疗、数据共享——PanCAN 的立场声明可以为医疗保健专业人员提供短期和长期管理该疾病患者的补充指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa1/10322133/4fa3e31ce6f4/oyad080_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa1/10322133/4fa3e31ce6f4/oyad080_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa1/10322133/4fa3e31ce6f4/oyad080_fig1.jpg

相似文献

1
Management of Patients With Pancreatic Cancer Using the "Right Track" Model.使用“正确轨道”模型管理胰腺癌患者。
Oncologist. 2023 Jul 5;28(7):584-595. doi: 10.1093/oncolo/oyad080.
2
Pancreatic Cancer Action Network's SPARK: A Cloud-Based Patient Health Data and Analytics Platform for Pancreatic Cancer.胰腺癌细胞行动网络的 SPARK:一个基于云的胰腺癌患者健康数据和分析平台。
JCO Clin Cancer Inform. 2024 Jan;8:e2300119. doi: 10.1200/CCI.23.00119.
3
Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience.利用胰腺癌患者的患者报告结局(PROs):胰腺癌细胞行动网络(PanCAN)在线患者注册经验。
Cancer Med. 2021 Oct;10(20):7152-7161. doi: 10.1002/cam4.4257. Epub 2021 Sep 3.
4
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
5
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.超越黑木树:影响澳大利亚地区、农村和偏远地区的健康研究问题的快速综述。
Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881.
6
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
The NCI All Ireland Cancer Conference.美国国家癌症研究所全爱尔兰癌症会议。
Oncologist. 1999;4(4):275-277.
9
[Pancreatic cancer. Evidence based management guidelines of the Hungarian Pancreatic Study Group].[胰腺癌。匈牙利胰腺癌研究小组基于证据的管理指南]
Orv Hetil. 2015 Feb 22;156(8):326-39. doi: 10.1556/OH.2015.30063.
10
Tuberculosis结核病

引用本文的文献

1
Baicalein inhibits DDX60 to suppress pancreatic cancer growth and regulate the tumor microenvironment.黄芩素通过抑制DDX60来抑制胰腺癌生长并调节肿瘤微环境。
Am J Transl Res. 2025 Aug 15;17(8):5885-5895. doi: 10.62347/TTQJ2494. eCollection 2025.
2
CD55 may be a new target for colorectal cancer treatment.CD55可能是结直肠癌治疗的一个新靶点。
Sci Rep. 2025 Jul 2;15(1):23086. doi: 10.1038/s41598-025-08491-4.
3
Understanding the Experiences of Patients With Pancreatic Cancer: Quantitative Analysis of the Pancreatic Cancer Action Network Patient Registry.

本文引用的文献

1
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
2
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.KRASG12D 小分子抑制剂在免疫功能正常的胰腺癌模型中的疗效。
Cancer Discov. 2023 Feb 6;13(2):298-311. doi: 10.1158/2159-8290.CD-22-1066.
3
Anti-tumor efficacy of a potent and selective non-covalent KRAS inhibitor.一种强效且选择性的非共价 KRAS 抑制剂的抗肿瘤功效。
了解胰腺癌患者的经历:胰腺癌行动网络患者登记处的定量分析
J Particip Med. 2025 May 26;17:e65046. doi: 10.2196/65046.
4
Pancreatic Cancer Patients Supportive Care Needs: A Qualitative Analysis.胰腺癌患者的支持性护理需求:一项定性分析。
Psychooncology. 2025 Mar;34(3):e70135. doi: 10.1002/pon.70135.
5
Sociodemographic characteristics associated with pancreatic cancer incidence and mortality among Blacks in the United States: a SEER-based study.美国黑人中与胰腺癌发病率和死亡率相关的社会人口学特征:一项基于监测、流行病学和最终结果(SEER)的研究
Am J Cancer Res. 2025 Feb 15;15(2):705-722. doi: 10.62347/GJCX1238. eCollection 2025.
6
Cancer mutationscape: revealing the link between modular restructuring and intervention efficacy among mutations.癌症突变景观:揭示突变之间模块化重构与干预效果之间的联系。
NPJ Syst Biol Appl. 2024 Jul 13;10(1):74. doi: 10.1038/s41540-024-00398-6.
7
Associations between Diabetes Mellitus and Selected Cancers.糖尿病与某些癌症之间的关联。
Int J Mol Sci. 2024 Jul 8;25(13):7476. doi: 10.3390/ijms25137476.
8
Dysbiosis Signature of Fecal Microbiota in Patients with Pancreatic Adenocarcinoma and Pancreatic Intraductal Papillary Mucinous Neoplasms.胰腺导管腺癌和胰腺导管内乳头状黏液性肿瘤患者粪便微生物群的生态失调特征
Biomedicines. 2024 May 8;12(5):1040. doi: 10.3390/biomedicines12051040.
9
Pancreatic cancer mutationscape: revealing the link between modular restructuring and intervention efficacy amidst common mutations.胰腺癌突变图谱:揭示常见突变中模块化重组与干预疗效之间的联系
bioRxiv. 2024 May 22:2024.01.27.577546. doi: 10.1101/2024.01.27.577546.
10
FROM LEFT TO RIGHT. PARA-AORTIC LYMPH NODES SAMPLING DURING PANCREATODUODENECTOMY FOR PANCREATIC CANCER.按从左至右的顺序进行胰腺十二指肠切除术时对胰周淋巴结进行采样。
Arq Bras Cir Dig. 2023 Nov 13;36:e1772. doi: 10.1590/0102-672020230054e1772. eCollection 2023.
Nat Med. 2022 Oct;28(10):2171-2182. doi: 10.1038/s41591-022-02007-7. Epub 2022 Oct 10.
4
Adagrasib in Non-Small-Cell Lung Cancer.阿达格拉西布治疗非小细胞肺癌
N Engl J Med. 2022 Sep 29;387(13):1238-1239. doi: 10.1056/NEJMc2210539.
5
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.针对非肺或甲状腺肿瘤的 RET 融合阳性实体瘤患者,塞普替尼的肿瘤不可知疗效和安全性(LIBRETTO-001):一项 1/2 期、开放标签、篮子试验。
Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: 10.1016/S1470-2045(22)00541-1. Epub 2022 Sep 12.
6
Dostarlimab: A Review.度伐利尤单抗:综述。
Biomolecules. 2022 Jul 26;12(8):1031. doi: 10.3390/biom12081031.
7
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.KRAS 野生型胰腺腺癌患者的分子特征。
Clin Cancer Res. 2022 Jun 13;28(12):2704-2714. doi: 10.1158/1078-0432.CCR-21-3581.
8
Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.DNA损伤反应通路存在基因突变的胰腺腺癌患者的预后:“了解你的肿瘤”项目的结果
JCO Precis Oncol. 2019 Dec;3:1-10. doi: 10.1200/PO.19.00115.
9
Model of Social Support for Patients Treated for Cancer.癌症治疗患者的社会支持模式
Cancers (Basel). 2021 Sep 24;13(19):4786. doi: 10.3390/cancers13194786.
10
Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience.利用胰腺癌患者的患者报告结局(PROs):胰腺癌细胞行动网络(PanCAN)在线患者注册经验。
Cancer Med. 2021 Oct;10(20):7152-7161. doi: 10.1002/cam4.4257. Epub 2021 Sep 3.